Robert F Siliciano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3240183/publications.pdf

Version: 2024-02-01

193	34,852	2795 94	3638 180
papers	citations	h-index	g-index

210	210	210	13312
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy. Science, 1997, 278, 1295-1300.	6.0	2,842
2	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine, 1999, 5, 512-517.	15.2	1,962
3	Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997, 387, 183-188.	13.7	1,921
4	Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine, 2003, 9, 727-728.	15.2	1,482
5	Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure. Cell, 2013, 155, 540-551.	13.5	1,207
6	In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nature Medicine, 1995, 1, 1284-1290.	15.2	709
7	Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation. Immunity, 2012, 36, 491-501.	6.6	680
8	Defective proviruses rapidly accumulate during acute HIV-1 infection. Nature Medicine, 2016, 22, 1043-1049.	15.2	605
9	The Challenge of Viral Reservoirs in HIV-1 Infection. Annual Review of Medicine, 2002, 53, 557-593.	5.0	575
10	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathogens, 2013, 9, e1003174.	2.1	524
11	Reservoirs for HIV-1: Mechanisms for Viral Persistence in the Presence of Antiviral Immune Responses and Antiretroviral Therapy. Annual Review of Immunology, 2000, 18, 665-708.	9.5	485
12	A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature, 2019, 566, 120-125.	13.7	471
13	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature, 2015, 517, 381-385.	13.7	469
14	A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature, 1988, 331, 78-81.	13.7	468
15	HIV Latency. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a007096-a007096.	2.9	447
16	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature Medicine, 2014, 20, 425-429.	15.2	436
17	Redefining the Viral Reservoirs that Prevent HIV-1 Eradication. Immunity, 2012, 37, 377-388.	6.6	414
18	Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell, 1988, 54, 561-575.	13.5	401

#	Article	IF	Citations
19	HIV-1 Integration Landscape during Latent and Active Infection. Cell, 2015, 160, 420-432.	13.5	393
20	Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 + T Cells. Journal of Virology, 2006, 80, 6441-6457.	1.5	377
21	An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. PLoS Pathogens, 2013, 9, e1003834.	2.1	360
22	Ex vivo analysis identifies effective HIV-1 latencyâ€“reversing drug combinations. Journal of Clinical Investigation, 2015, 125, 1901-1912.	3.9	340
23	Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. Journal of Experimental Medicine, 2017, 214, 959-972.	4.2	327
24	Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART. JAMA - Journal of the American Medical Association, 2005, 293, 817.	3.8	323
25	Resting CD4 + T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes. Journal of Virology, 2004, 78, 6122-6133.	1.5	306
26	Control of HIV despite the Discontinuation of Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1683-1683.	13.9	305
27	Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature Medicine, 2008, 14, 762-766.	15.2	295
28	Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host and Microbe, 2017, 21, 494-506.e4.	5.1	289
29	Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature, 1985, 317, 428-430.	13.7	288
30	Targeting the Latent Reservoir for HIV-1. Immunity, 2018, 48, 872-895.	6.6	282
31	The HBV Drug Entecavir â€" Effects on HIV-1 Replication and Resistance. New England Journal of Medicine, 2007, 356, 2614-2621.	13.9	279
32	HIV reservoirs: what, where and how to target them. Nature Reviews Microbiology, 2016, 14, 55-60.	13.6	259
33	Isolation and Characterization of Replication-Competent Human Immunodeficiency Virus Type 1 from a Subset of Elite Suppressors. Journal of Virology, 2007, 81, 2508-2518.	1.5	257
34	Maintenance of viral suppression in HIV-1â€“infected HLA-B*57+ elite suppressors despite CTL escape mutations. Journal of Experimental Medicine, 2006, 203, 1357-1369.	4.2	250
35	Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13475-13480.	3.3	249
36	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature, 2020, 585, 261-267.	13.7	245

#	Article	IF	Citations
37	Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. PLoS Pathogens, 2013, 9, e1003347.	2.1	244
38	Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay. PLoS Pathogens, 2013, 9, e1003398.	2.1	228
39	Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2002, 76, 8518-8531.	1.5	227
40	Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. Journal of Clinical Investigation, 2009, 119, 3473-86.	3.9	224
41	Enhanced Culture Assay for Detection and Quantitation of Latently Infected, Resting CD4⁺ T-Cells Carrying Replication-Competent Virus in HIV-1-Infected Individuals. , 2005, 304, 003-016.		216
42	Viral Dynamics in HIV-1 Infection. Cell, 1998, 93, 665-671.	13.5	215
43	The multifactorial nature of HIV-1 latency. Trends in Molecular Medicine, 2004, 10, 525-531.	3.5	215
44	BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle, 2013, 12, 452-462.	1.3	209
45	Screening for noise in gene expression identifies drug synergies. Science, 2014, 344, 1392-1396.	6.0	202
46	Kinetics of Human Immunodeficiency Virus Type 1 Decay following Entry into Resting CD4 + T Cells. Journal of Virology, 2005, 79, 2199-2210.	1.5	190
47	Orientation-Dependent Regulation of Integrated HIV-1 Expression by Host Gene Transcriptional Readthrough. Cell Host and Microbe, 2008, 4, 134-146.	5.1	190
48	Experimental approaches to the study of HIV-1 latency. Nature Reviews Microbiology, 2007, 5, 95-106.	13.6	187
49	Genotypic Analysis of HIVâ€1 Drug Resistance at the Limit of Detection: Virus Production without Evolution in Treated Adults with Undetectable HIV Loads. Journal of Infectious Diseases, 2004, 189, 1452-1465.	1.9	186
50	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	3.9	186
51	Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. Journal of Allergy and Clinical Immunology, 2008, 122, 22-28.	1.5	183
52	The mTOR Complex Controls HIV Latency. Cell Host and Microbe, 2016, 20, 785-797.	5.1	179
53	Towards an HIV-1 cure: measuring the latent reservoir. Trends in Microbiology, 2015, 23, 192-203.	3.5	177
54	Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T Cells. PLoS Pathogens, 2006, 2, e68.	2.1	174

#	Article	IF	Citations
55	Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 ⁺ T Cell Model without Inducing Global T Cell Activation. Journal of Virology, 2011, 85, 6060-6064.	1.5	174
56	Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2575-E2584.	3.3	173
57	Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2002, 76, 4138-4144.	1.5	171
58	Stability of the Latent Reservoir for HIVâ€1 in Patients Receiving Valproic Acid. Journal of Infectious Diseases, 2007, 195, 833-836.	1.9	169
59	Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1. Journal of Virology, 2004, 78, 1718-1729.	1.5	168
60	A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy. Clinical Infectious Diseases, 2014, 58, 883-890.	2.9	166
61	Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization. Journal of Experimental Medicine, 1997, 185, 909-920.	4.2	164
62	Analysis of Human Immunodeficiency Virus Type 1 Gene Expression in Latently Infected Resting CD4 + T Lymphocytes In Vivo. Journal of Virology, 2003, 77, 7383-7392.	1.5	163
63	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection. Immunity, 2017, 47, 766-775.e3.	6.6	160
64	Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nature Medicine, 2012, 18, 1378-1385.	15.2	159
65	Latency in Human Immunodeficiency Virus Type 1 Infection: No Easy Answers. Journal of Virology, 2003, 77, 1659-1665.	1.5	158
66	Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. Journal of Clinical Investigation, 2018, 128, 876-889.	3.9	157
67	Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy. Journal of Virology, 2006, 80, 4758-4770.	1.5	156
68	Chronic CD4⁺T-Cell Activation and Depletion in Human Immunodeficiency Virus Type 1 Infection: Type I Interferon-Mediated Disruption of T-Cell Dynamics. Journal of Virology, 2008, 82, 1870-1883.	1.5	155
69	Gâ†'A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo. Journal of Virology, 2005, 79, 1975-1980.	1.5	154
70	Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV. Cell, 2012, 148, 1271-1283.	13.5	152
71	A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children. Journal of Clinical Investigation, 2000, 105, 995-1003.	3.9	151
72	The Human Immunodeficiency Virus Type 1gag Gene Encodes an Internal Ribosome Entry Site. Journal of Virology, 2001, 75, 181-191.	1.5	145

#	Article	IF	Citations
73	A quantitative basis for antiretroviral therapy for HIV-1 infection. Nature Medicine, 2012, 18, 446-451.	15.2	143
74	Differential decay of intact and defective proviral DNA in HIV-1â€“infected individuals on suppressive antiretroviral therapy. JCI Insight, 2020, 5, .	2.3	140
75	Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 7824-7833.	1.5	139
76	A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy. Journal of Virology, 2009, 83, 9247-9257.	1.5	138
77	Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4 + T Cells In Vivo. Journal of Virology, 2004, 78, 9105-9114.	1.5	136
78	Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discovery Today, 2013, 18, 541-551.	3.2	131
79	Preservation of FoxP3⁺Regulatory T Cells in the Peripheral Blood of Human Immunodeficiency Virus Type 1-Infected Elite Suppressors Correlates with Low CD4⁺T-Cell Activation. Journal of Virology, 2008, 82, 8307-8315.	1.5	125
80	Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. Aids, 2017, 31, 5-14.	1.0	123
81	Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4 ⁺ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy. Journal of Virology, 2009, 83, 8470-8481.	1.5	122
82	The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. Journal of Immunology, 2016, 197, 407-417.	0.4	121
83	Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. Journal of Clinical Investigation, 2013, 123, 3848-3860.	3.9	120
84	Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure. Journal of Virology, 2002, 76, 9481-9492.	1.5	119
85	Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4832-4837.	3.3	119
86	Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. Open Forum Infectious Diseases, 2015, 2, ofv123.	0.4	119
87	Resting CD4 + T Lymphocytes but Not Thymocytes Provide a Latent Viral Reservoir in a Simian Immunodeficiency Virus- Macaca nemestrina Model of Human Immunodeficiency Virus Type 1-Infected Patients on Highly Active Antiretroviral Therapy. Journal of Virology, 2003, 77, 4938-4949.	1.5	117
88	Control of HIV-1 in Elite Suppressors despite Ongoing Replication and Evolution in Plasma Virus. Journal of Virology, 2010, 84, 7018-7028.	1.5	116
89	A long-term latent reservoir for HIV-1: discovery and clinical implications. Journal of Antimicrobial Chemotherapy, 2004, 54, 6-9.	1.3	112
90	Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring. Clinical Infectious Diseases, 2006, 42, 1189-1196.	2.9	112

#	Article	IF	Citations
91	HIV latency and integration site placement in five cell-based models. Retrovirology, 2013, 10, 90.	0.9	104
92	Antigen-driven clonal selection shapes the persistence of HIV-1â€“infected CD4+ T cells in vivo. Journal of Clinical Investigation, 2021, 131, .	3.9	103
93	HIV-1 viral load blips are of limited clinical significance. Journal of Antimicrobial Chemotherapy, 2006, 57, 803-805.	1.3	102
94	Influence of Host Gene Transcription Level and Orientation on HIV-1 Latency in a Primary-Cell Model. Journal of Virology, 2011, 85, 5384-5393.	1.5	102
95	HIV-1 DNA Is Detected in Bone Marrow Populations Containing CD4+ T Cells but Is not Found in Purified CD34+ Hematopoietic Progenitor Cells in Most Patients on Antiretroviral Therapy. Journal of Infectious Diseases, 2012, 205, 1014-1018.	1.9	102
96	Nuclear landscape of HIV-1 infection and integration. Nature Reviews Microbiology, 2017, 15, 69-82.	13.6	101
97	Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads. Journal of Virology, 2004, 78, 968-979.	1.5	98
98	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	15.2	96
99	Measuring the Frequency of Latent HIV-1 in Resting CD4+ T Cells Using a Limiting Dilution Coculture Assay. Methods in Molecular Biology, 2016, 1354, 239-253.	0.4	92
100	Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells. Nature, 1993, 364, 158-161.	13.7	91
101	Transmission of Human Immunodeficiency Virus Type 1 from a Patient Who Developed AIDS to an Elite Suppressor. Journal of Virology, 2008, 82, 7395-7410.	1.5	90
102	Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1. Journal of Allergy and Clinical Immunology, 2014, 134, 12-19.	1.5	88
103	HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. Journal of Clinical Investigation, 2018, 128, 3102-3115.	3.9	88
104	CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells. PLoS ONE, 2014, 9, e110731.	1.1	88
105	Developing strategies for HIV-1 eradication. Trends in Immunology, 2012, 33, 554-562.	2.9	87
106	Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathogens, 2016, 12, e1005535.	2.1	85
107	Role of Natural Killer Cells in a Cohort of Elite Suppressors: Low Frequency of the Protective KIR3DS1 Allele and Limited Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro. Journal of Virology, 2009, 83, 5028-5034.	1.5	83
108	A Novel PCR Assay for Quantification of HIV-1 RNA. Journal of Virology, 2013, 87, 6521-6525.	1.5	78

#	Article	IF	Citations
109	Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure. Annual Review of Medicine, 2016, 67, 215-228.	5.0	75
110	Different human resting memory CD4 ⁺ T cell subsets show similar low inducibility of latent HIV-1 proviruses. Science Translational Medicine, 2020, 12, .	5.8	73
111	Genotypic Resistance in HIVâ€1â€“Infected Patients with Persistently Detectable Lowâ€Level Viremia while Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 39, 1030-1037.	2.9	72
112	From reactivation of latent HIVâ€1 to elimination of the latent reservoir: The presence of multiple barriers to viral eradication. BioEssays, 2013, 35, 544-552.	1.2	72
113	The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. Cell Host and Microbe, 2019, 26, 73-85.e4.	5.1	71
114	Longitudinal study reveals HIV-1â€“infected CD4+ T cell dynamics during long-term antiretroviral therapy. Journal of Clinical Investigation, 2020, 130, 3543-3559.	3.9	69
115	Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART. PLoS Pathogens, 2007, 3, e122.	2.1	67
116	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18692-18700.	3.3	67
117	No Evidence for Decay of the Latent Reservoir in HIVâ€1â€“Infected Patients Receiving Intensive Enfuvirtideâ€Containing Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 293-296.	1.9	64
118	A mechanistic theory to explain the efficacy of antiretroviral therapy. Nature Reviews Microbiology, 2014, 12, 772-780.	13.6	64
119	CMPK2 and BCL-G are associated with type 1 interferonâ€“induced HIV restriction in humans. Science Advances, 2018, 4, eaat0843.	4.7	64
120	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. Journal of Clinical Investigation, 2017, 127, 651-656.	3.9	64
121	A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs. Science Translational Medicine, 2011, 3, 91ra63.	5.8	62
122	Recent developments in the effort to cure HIV infection: going beyond N = 1. Journal of Clinical Investigation, 2016, 126, 409-414.	3.9	62
123	HIV-1 eradication strategies. Current Opinion in HIV and AIDS, 2013, 8, 1.	1.5	60
124	Re-evaluating evolution in the HIV reservoir. Nature, 2017, 551, E6-E9.	13.7	60
125	Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir. Retrovirology, 2018, 15, 21.	0.9	58
126	Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nature Communications, 2012, 3, 716.	5.8	57

#	Article	IF	Citations
127	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Science Translational Medicine, 2021, 13, .	5.8	54
128	Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Current Opinion in Immunology, 2004, 16, 470-476.	2.4	53
129	Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality. PLoS Pathogens, 2016, 12, e1005689.	2.1	52
130	Insight into treatment of <scp>HIV</scp> infection from viral dynamics models. Immunological Reviews, 2018, 285, 9-25.	2.8	51
131	The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. Aids, 2008, 22, 541-544.	1.0	50
132	Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6321-6326.	3.3	47
133	Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology, 2011, 8, 97.	0.9	47
134	HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. Journal of Virology, 2016, 90, 4511-4519.	1.5	47
135	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. Journal of Virology, 2021, 95, .	1.5	47
136	HLA-B*57 Elite Suppressor and Chronic Progressor HIV-1 Isolates Replicate Vigorously and Cause CD4 ⁺ T Cell Depletion in Humanized BLT Mice. Journal of Virology, 2014, 88, 3340-3352.	1.5	46
137	A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nature Protocols, 2014, 9, 2755-2770.	5.5	46
138	Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	46
139	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32066-32077.	3.3	44
140	The role of CD32 during HIV-1 infection. Nature, 2018, 561, E17-E19.	13.7	43
141	Recent trends in HIV-1 drug resistance. Current Opinion in Virology, 2013, 3, 487-494.	2.6	40
142	Evolution of the HIV-1 nefgene in HLA-B*57 Positive Elite Suppressors. Retrovirology, 2010, 7, 94.	0.9	39
143	Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. Journal of Antimicrobial Chemotherapy, 2012, 67, 398-403.	1.3	39
144	Engaging innate immunity in HIV-1 cure strategies. Nature Reviews Immunology, 2022, 22, 499-512.	10.6	39

#	Article	IF	Citations
145	Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells. ELife, 2016, 5, .	2.8	37
146	In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 271-294.	9.6	37
147	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. Annals of Internal Medicine, 2022, 175, 95-100.	2.0	36
148	Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial. AIDS and Behavior, 2019, 23, 2337-2346.	1.4	34
149	Impact of Antiâ€“PD-1 and Antiâ€“CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clinical Infectious Diseases, 2021, 73, e1973-e1981.	2.9	34
150	The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Current Opinion in HIV and AIDS, 2006, 1, 121-8.	1.5	32
151	Reservoir expansion by T-cell proliferation may be another barrier to curing HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1692-1694.	3.3	31
152	Assays to Measure Latency, Reservoirs, and Reactivation. Current Topics in Microbiology and Immunology, 2017, 417, 23-41.	0.7	31
153	Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antiviral Therapy, 2009, 14, 263-271.	0.6	30
154	Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure. Journal of Infectious Diseases, 2021, 223, S13-S21.	1.9	29
155	HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15763-15771.	3.3	28
156	The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. Current Opinion in HIV and AIDS, 2006, 1, 62-68.	1.5	27
157	Endothelial Cell Stimulation Overcomes Restriction and Promotes Productive and Latent HIV-1 Infection of Resting CD4 ⁺ T Cells. Journal of Virology, 2013, 87, 9768-9779.	1.5	26
158	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. Nature Communications, 2021, 12, 1474.	5.8	26
159	Short Communication: Dynamic Constraints on the Second Phase Compartment of HIV-Infected Cells. AIDS Research and Human Retroviruses, 2011, 27, 759-761.	0.5	23
160	Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 ⁺ T Cells. Journal of Virology, 2020, 95, .	1.5	23
161	Finding a Cure for Human Immunodeficiency Virus-1 Infection. Infectious Disease Clinics of North America, 2014, 28, 633-650.	1.9	22
162	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. ACS Medicinal Chemistry Letters, 2015, 6, 1075-1079.	1.3	22

#	Article	IF	Citations
163	HIV persistence: clonal expansion of cells in the latent reservoir. Journal of Clinical Investigation, 2017, 127, 2536-2538.	3.9	21
164	Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. Clinical Infectious Diseases, 2017, 65, 1308-1315.	2.9	20
165	Not-so-innocent bystanders. Nature, 2014, 505, 492-493.	13.7	19
166	Early treatment may not be early enough. Nature, 2014, 512, 35-36.	13.7	19
167	Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions. PLoS Pathogens, 2016, 12, e1005679.	2.1	19
168	Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2005, 13, 96-100.	2.9	18
169	Treatment Implications of the Latent Reservoir for HIVâ€1. Advances in Pharmacology, 2007, 55, 411-425.	1.2	15
170	Rekindled HIV infection. Science, 2014, 345, 1005-1006.	6.0	15
171	Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists. Journal of Clinical Investigation, 2020, 130, 5665-5667.	3.9	15
172	What do we need to do to cure HIV infection. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 104-8.	2.9	15
173	Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. AIDS Research and Human Retroviruses, 2013, 29, 1434-1442.	0.5	14
174	Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. Journal of Infectious Diseases, 2020, 224, 258-268.	1.9	14
175	Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses. PLoS ONE, 2018, 13, e0192098.	1.1	14
176	Quantitative evaluation of the antiretroviral efficacy of dolutegravir. JCI Insight, 2016, 1, e90033.	2.3	13
177	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. Nature Communications, 2022, 13, .	5.8	12
178	Biomarkers of HIV replication. Current Opinion in HIV and AIDS, 2010, 5, 491-497.	1.5	11
179	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	2.1	11
180	TCR-mimic bispecific antibodies to target the HIV-1 reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123406119.	3.3	10

#	Article	IF	Citations
181	Reservoirs for HIV-1. Current Infectious Disease Reports, 1999, 1, 298-304.	1.3	8
182	Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6860-6861.	3.3	8
183	Multiple genetic programs contribute to CD4 T cell memory differentiation and longevity by maintaining T cell quiescence. Cellular Immunology, 2020, 357, 104210.	1.4	8
184	Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. Journal of Infectious Diseases, 2021, 223, 1905-1913.	1.9	8
185	Immune alteration fends off AIDS. Nature Medicine, 2008, 14, 1016-1018.	15.2	5
186	Stoichiometric parameters of HIV-1 entry. Virology, 2015, 474, 1-9.	1.1	5
187	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 ⁺ and Gut CD4 ⁺ T Cells. Journal of Virology, 2020, 95, .	1.5	4
188	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	2.9	4
189	Measurement of antiviral activity in drugs for HIV-1. Lancet Infectious Diseases, The, 2011, 11, 888-889.	4.6	2
190	Making Sense of HIV Innate Sensing. Immunity, 2013, 39, 998-1000.	6.6	2
191	HIV Prevention and Treatment Fields Join Forces. EBioMedicine, 2014, 1, 4-5.	2.7	2
192	Editorial: JQ1: giving HIV-1 expression a boost by blocking bromodomains?. Journal of Leukocyte Biology, 2012, 92, 1127-1129.	1.5	1
193	Reply. Journal of Allergy and Clinical Immunology, 2015, 136, 214.	1.5	0